Skip to main content

Analysis of survival by tumor response: have we learnt any better?

Annals of Hematology volume 94, pages 1615–1616 (2015)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Delgado J, Pereira A, Villamor N, López-Guillermo A, Rozman C (2014) Survival analysis in hematologic malignancies: recommendations for clinicians. Haematologica 99:1410–1420

    PubMed  Article  Google Scholar 

  2. Anderson JR, Cain KC, Gelber RD (1983) Analysis of survival by tumor response. J Clin Oncol 1:710–719

    CAS  PubMed  Google Scholar 

  3. Anderson JR, Cain KC, Gelber RD (2008) Analysis of survival by tumor response and other comparisons of time-to event by outcome variables. J Clin Oncol 26:3913–3915

    PubMed  Article  Google Scholar 

  4. Zago M, Oehrlein K, Rendl C, Hahn-Ast C, Kanz L, Weisel K (2014) Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment. Ann Hematol 93:1993–1999

    CAS  PubMed  Article  Google Scholar 

  5. Haas PS, Denz U, Ihorst G, Engelhardt M (2008) Thalidomide in consecutive multiple myeloma patients: single-center analysis on practical aspects, efficacy, side effects and prognostic factors with lower thalidomide doses. Eur J Haematol 80:303–309

    CAS  PubMed  Article  Google Scholar 

  6. Engelhardt M, Terpos E, Kleber M, Gay F, Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, Johnsen HE, Hajek R, Driessen C, Ludwig H, Beksac M, Boccadoro M, Straka C, Brighen S, Gramatzki M, Larocca A, Lokhorst H, Magarotto V, Morabito F, Dimopoulos MA, Einsele H, Sonneveld P, Palumbo A (2014) European Myeloma Network. European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica 99:232–242

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  7. Engelhardt M, Wäsch R, Reinhardt H, Kleber M (2014) Pomalidomide. Recent Results Cancer Res 201:359–372

    CAS  PubMed  Article  Google Scholar 

  8. Udi J, Schüler J, Wider D, Ihorst G, Catusse J, Waldschmidt J, Schnerch D, Follo M, Wäsch R, Engelhardt M (2013) Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization. Br J Haematol 161:104–116

    CAS  PubMed  Article  Google Scholar 

  9. Schüler J, Ewerth D, Waldschmidt J, Wäsch R, Engelhardt M (2013) Preclinical models of multiple myeloma: a critical appraisal. Expert Opin Biol Ther 13:S111–S123

    PubMed  Article  Google Scholar 

  10. Szydlo RM (2001) Surviving survival analysis. Bone Marrow Transplant 28:907

    CAS  PubMed  Article  Google Scholar 

Download references

Acknowledgments

The work is supported through Deutsche Krebshilfe grants no. 109569 + no. 111424 (ME, RW).

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Affiliations

  1. Center of Clinical Trials, University Medical Center Freiburg, Freiburg, Germany

    Gabriele Ihorst & Monika Engelhardt

  2. Department of Hematology and Oncology, University Medical Center Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany

    Johannes Waldschmidt & Ralph Wäsch

  3. Department of Medical Biometry and Statistics (IMBI), University of Freiburg, Freiburg, Germany

    Martin Schumacher

Authors
  1. Gabriele Ihorst
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johannes Waldschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin Schumacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ralph Wäsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Monika Engelhardt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Monika Engelhardt.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ihorst, G., Waldschmidt, J., Schumacher, M. et al. Analysis of survival by tumor response: have we learnt any better?. Ann Hematol 94, 1615–1616 (2015). https://doi.org/10.1007/s00277-015-2426-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-015-2426-8

Keywords

  • Overall Survival
  • Lenalidomide
  • Landmark Analysis
  • Fixed Time Point
  • Adverse Event Experience